Key Takeaways
- • Digital health startups raised $4 billion across 110 deals in Q1 2026, up 33% from $3 billion across 122 deals in Q1 2025, driven by 12 megadeals valued at $100 million or more.
- • Average deal size reached $36.7 million in Q1 2026, the highest since Q4 2021, signaling investor appetite for larger, more mature digital health companies.
- • WHOOP's $575 million Series G funding round was the quarter's largest deal, followed by Verily ($300 million), OpenEvidence ($250 million), Talkiatry ($210 million), eMed ($200 million), and Grow Therapy ($150 million).
- • M&A activity increased modestly with 43 digital health transactions in Q1 2026 versus 30 in Q4 2025; notable acquirers included OpenAI (purchasing health data startup Torch) and Headway (acquiring AI recruiting agent maker Tezi) in talent-acquisition plays rather than revenue-focused acquisitions.
- • Rock Health projects approximately 50 megadeals for full-year 2026 if Q1 pace continues—nearly double the 26 megadeals recorded in 2025—though investors remain selective amid geopolitical uncertainty and regulatory volatility.
Summary
Digital health venture funding rebounded significantly in the first quarter of 2026, marking a notable inflection point after several uneven years for the sector. According to data released by Rock Health, a venture fund and strategy group, digital health startups raised $4 billion across 110 deals during Q1 2026—a $1 billion increase compared to Q1 2025's $3 billion across 122 deals. The improvement was driven largely by a wave of 12 megadeals valued at $100 million or more, which substantially elevated the average financing size to $36.7 million, the highest quarterly average since Q4 2021.
Deal composition shifted toward larger, more established companies. WHOOP, a wearable device manufacturer, led the quarter with a $575 million Series G funding round that valued the company at $10 billion. The five largest deals following WHOOP were concentrated in precision health and mental health verticals: Verily raised $300 million for AI-powered precision health initiatives; OpenEvidence secured $250 million for its AI-powered healthcare search platform; Talkiatry obtained $210 million for telepsychiatry services; eMed closed a $200 million round for employer-focused GLP-1 clinic services; and Grow Therapy raised $150 million to expand employer and health system partnerships. If this quarterly pace sustains through 2026, Rock Health projects approximately 50 megadeals for the full year—nearly double the 26 megadeals recorded in 2025.
Mergers and acquisitions activity showed more modest growth, with 43 digital health deals closing in Q1 2026 compared to 30 transactions in Q4 2025. Notable among these were acquisitions focused on talent acquisition rather than revenue consolidation: OpenAI's purchase of health data startup Torch and Headway's acquisition of Tezi, an autonomous AI recruiting agent. Conversely, a major venture collapsed during the quarter when New Mountain Capital's $30+ billion deal to combine five health tech portfolio companies—led by former managing director Matt Holt—fell apart in March due to governance and financing disagreements.
Rock Health emphasized that the digital health market is expected to remain volatile given ongoing geopolitical tensions, shifting federal priorities, and evolving healthcare regulations. The firm noted that investors are concentrating capital on startups with demonstrated paths to sustainable growth and financial stability. Additionally, Q1 2026 marked the first quarter in which Rock Health discontinued distinguishing between AI-enabled and non-AI digital health startups, reflecting the market reality that artificial intelligence capability has become embedded across virtually all digital health ventures rather than a differentiated category.
Deal composition shifted toward larger, more established companies. WHOOP, a wearable device manufacturer, led the quarter with a $575 million Series G funding round that valued the company at $10 billion. The five largest deals following WHOOP were concentrated in precision health and mental health verticals: Verily raised $300 million for AI-powered precision health initiatives; OpenEvidence secured $250 million for its AI-powered healthcare search platform; Talkiatry obtained $210 million for telepsychiatry services; eMed closed a $200 million round for employer-focused GLP-1 clinic services; and Grow Therapy raised $150 million to expand employer and health system partnerships. If this quarterly pace sustains through 2026, Rock Health projects approximately 50 megadeals for the full year—nearly double the 26 megadeals recorded in 2025.
Mergers and acquisitions activity showed more modest growth, with 43 digital health deals closing in Q1 2026 compared to 30 transactions in Q4 2025. Notable among these were acquisitions focused on talent acquisition rather than revenue consolidation: OpenAI's purchase of health data startup Torch and Headway's acquisition of Tezi, an autonomous AI recruiting agent. Conversely, a major venture collapsed during the quarter when New Mountain Capital's $30+ billion deal to combine five health tech portfolio companies—led by former managing director Matt Holt—fell apart in March due to governance and financing disagreements.
Rock Health emphasized that the digital health market is expected to remain volatile given ongoing geopolitical tensions, shifting federal priorities, and evolving healthcare regulations. The firm noted that investors are concentrating capital on startups with demonstrated paths to sustainable growth and financial stability. Additionally, Q1 2026 marked the first quarter in which Rock Health discontinued distinguishing between AI-enabled and non-AI digital health startups, reflecting the market reality that artificial intelligence capability has become embedded across virtually all digital health ventures rather than a differentiated category.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.